ArticleThe Journal of clinical investigation2024

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.

Dezhi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.